<DOC>
	<DOCNO>NCT00972114</DOCNO>
	<brief_summary>The purpose study phase I/II safety efficacy study evaluate clinical effect coronary artery bypass graft ( CABG ) combine pedicled omentum wrap autologous atrial tissue patch cardiomyoplasty patient ischemic cardiomyopathy .</brief_summary>
	<brief_title>CABG Combined Pedicled Omentum Wrapped Autologous Atrial Tissue Patch Cardiomyoplasty Ischemic Cardiomyopathy</brief_title>
	<detailed_description>This phase I/II , randomize control trial evaluate use CABG combine pedicled omentum wrap autologous atrial tissue patch cardiomyoplasty patient ischemic cardiomyopathy . The study hypothesis combine surgical technique perform pedicled omentum wrap autologous atrial tissue patch cardiomyoplasty adjunct CABG , safe patient severe ischemic heart failure improve regional myocardial perfusion contractility , result improve systolic diastolic leave ventricular function . The primary object study evaluate safety efficacy novel combine surgical technique . The efficacy assess change leave ventricular ejection fraction MRI . The secondary endpoint study assess effect novel combine surgical technique cardiac contractile function functional outcome . The effect assess basis clinical status image rest 6 month follow-up enrollment . A maximum 60 patient 20 70 year enrol study . These participant randomize receive CABG , pedicled omentum graft combine CABG , pedicled omentum graft autologous atrial tissue patch cardiomyoplasty combine CABG . The objective evaluation perform baseline 6 month follow-up .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>Male female ; 2070 year old ; Ability give informed consent ; Documented severe coronary heart disease , define least 70 % luminal diameter narrow least three major coronary artery , suit CABG ; Left ventricular dysfunction ( LVEF ) less equal 35 % , measure MRI less equal 45 % , measure echocardiogram ; Presence reversibility , identify single photon emission compute tomography ( SPECT ) isotope protocol ; At least 3 month since last episode myocardial infarction ; Without history abdominal operation severe abdominal disease ; Negative pregnancy test ( woman childbearing potential . Pregnant lactating ; A history malignancy last 5 year exclude basal cell carcinoma , surgically remove , proof surgical clean margin ; history abdominal operation severe abdominal disease ; Positive test result human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C Any condition require immunosuppressive medication ; Bleeding diathesis , define international normalized ratio least 2.0 absence warfarin therapy ; Hepatic dysfunction , define aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) 1.5 time upper limit normal range prior study entry ; Chronic renal insufficiency , define serum creatinine level great 2.5 mg/dL require dialysis ; Leukocytes le 4,000/µL exceed 10,000/µL ; Platelets le 100,000/µL ; Hemoglobin le 10 g/dL ; Chronic atrial fibrillation ; Less 3 month since last episode cerebral infarction ; Implantable cardioverterdefibrillator shock within 30 day baseline consent , within 30 day randomization ; Presence ventricular tachycardia last 30 second 24hour Holter monitor electrocardiogram ( ECG ) perform screening period ; Patients impossible perform cardiac MRI ; Enrolled investigational device drug study within previous1 year ; Any reason Clinical Supervisors Clinical Researchers may consider case unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>